Vor Biopharma Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Vor Biopharma Inc. (VOR) reported Increase (Decrease) in Prepaid Expense and Other Assets of $6.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$278.00K.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $6.36M, a 2652.81% increase year-over-year.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $873.00K.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $75.00K, a 55.62% decline year-over-year.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.68M, a 301.68% decline from fiscal 2024.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $835.00K.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$3.27M.
- Vor Biopharma Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$225.00K, a 103.54% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.08M 10-Q · filed 2026-08-11 | $6.95M derived: sum of 3 quarters · filed 2026-08-11 | $7.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.36M 10-Q · filed 2026-05-13 | $7.23M derived: sum of 2 quarters · filed 2026-05-13 | $7.31M derived: sum of 3 quarters · filed 2026-05-13 | $4.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $873.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $948.00K derived: sum of 2 quarters · filed 2026-03-30 | -$1.92M derived: sum of 3 quarters · filed 2026-08-11 | -$1.68M 10-K · filed 2026-03-30 |
| 2025-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.79M derived: sum of 2 quarters · filed 2026-08-11 | -$2.56M 10-Q · filed 2025-11-13 | -$2.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.63M 10-Q · filed 2026-08-11 | -$2.66M derived: sum of 3 quarters · filed 2026-08-11 | -$2.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $231.00K 10-Q · filed 2026-05-13 | $207.00K derived: sum of 2 quarters · filed 2026-05-13 | $376.00K derived: sum of 3 quarters · filed 2026-05-13 | $356.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $145.00K derived: sum of 2 quarters · filed 2026-03-30 | $125.00K derived: sum of 3 quarters · filed 2026-03-30 | $835.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $149.00K derived: sum of 2 quarters · filed 2025-11-13 | $859.00K 10-Q · filed 2025-11-13 | $147.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $690.00K 10-Q · filed 2025-08-12 | -$22.00K derived: sum of 3 quarters · filed 2025-08-12 | -$366.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $710.00K 10-Q · filed 2025-05-14 | -$2.00K derived: sum of 2 quarters · filed 2025-05-14 | -$346.00K derived: sum of 3 quarters · filed 2025-05-14 | -$2.55M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$712.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$1.06M derived: sum of 2 quarters · filed 2025-03-20 | -$3.26M derived: sum of 3 quarters · filed 2025-03-20 | -$3.27M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$2.55M derived: sum of 2 quarters · filed 2024-11-07 | -$2.56M 10-Q · filed 2024-11-07 | -$2.47M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.21M 10-Q · filed 2024-08-08 | -$2.12M derived: sum of 3 quarters · filed 2024-08-08 | -$3.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$7.00K 10-Q · filed 2024-05-09 | $84.00K derived: sum of 2 quarters · filed 2024-05-09 | -$960.00K derived: sum of 3 quarters · filed 2024-05-09 | -$1.97M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$953.00K derived: sum of 2 quarters · filed 2024-03-20 | -$1.97M derived: sum of 3 quarters · filed 2024-03-20 | -$225.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.06M derived: sum of 2 quarters · filed 2023-11-07 | -$316.00K 10-Q · filed 2023-11-07 | $510.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $728.00K 10-Q · filed 2023-08-10 | $1.55M derived: sum of 3 quarters · filed 2023-08-10 | $3.03M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.74M 10-Q · filed 2023-05-11 | $2.57M derived: sum of 2 quarters · filed 2023-05-11 | $4.04M derived: sum of 3 quarters · filed 2023-05-11 | $4.97M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.30M derived: sum of 2 quarters · filed 2023-03-23 | $3.23M derived: sum of 3 quarters · filed 2023-03-23 | $6.36M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.41M derived: sum of 2 quarters · filed 2022-11-10 | $5.54M 10-Q · filed 2022-11-10 | $4.08M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $933.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.06M 10-Q · filed 2022-08-11 | $2.61M derived: sum of 3 quarters · filed 2022-08-11 | $3.13M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $3.13M 10-Q · filed 2022-05-12 | $1.68M derived: sum of 2 quarters · filed 2022-05-12 | $2.19M derived: sum of 3 quarters · filed 2022-05-12 | $2.18M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$936.00K derived: sum of 2 quarters · filed 2022-03-14 | -$953.00K derived: sum of 3 quarters · filed 2022-03-14 | -$606.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $517.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $500.00K derived: sum of 2 quarters · filed 2021-11-10 | $847.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $330.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $347.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |